Table 2. Human cells lines and their therapeutic protein products^a,b.

Cell line	Product	Indication	FDA approval status	EMA approval status
HEK293
	Drotrecogin alfa	Severe septicemia/septic shock	Approved 2001;  withdrawn 2011	Approved 2002;  withdrawn 2011
	rFVIIIFc	Hemophilia A	Approved 2014	Submitted 2014
	rFIXFc	Hemophilia B	Approved 2014	NA
	Dulaglutide	Type 2 diabetes	Approved 2014	Submitted 2014
	Human-cl rhFVIII	Hemophilia A	Submitted to the FDA	Approved 2014
HT-1080
	Agalsidase alfa	Fabry disease	NA	Approved 2001
	Epoetin delta	Anemia secondary to chronic renal failure	NA	Approved 2002;  withdrawn 2009 (Europe)
	Idursulfase	Hunter syndrome	Approved 2006	Approved 2007
	Velaglucerase alfa	Type 1 Gaucher disease	Approved 2010	Approved 2010
PER.C6
	CL184	Rabies virus infection	Submitted to the FDA	NA
	MOR103	Rheumatoid arthritis, multiple sclerosis	Phase 1 clinical development	Phase 1 clinical development

FDA, US Food and Drug Administration; EMA, European Medicines Agency; HEK, human embryonic kidney; NA, not approved; rFVIIIFc, recombinant factor VIII Fc fusion protein; rFIXFc, recombinant factor IX Fc fusion protein; rhFVIII, recombinant human factor VIII.

^aData obtained from publically available resources (October 2014); all approved products may not be included.

^bReferences: (ALPROLIX®, 2014; Bakker et al., 2005; Behrens et al., 2014; Casademunt et al., 2012; DYNEPO®, 2007; ELAPRASE®, 2012, 2013; ELOCTATE®, 2014; European Medicines Agency and Committee for Medicinal Products for Human Use, 2014; Glaesner et al., 2010; Octapharma, 2014; REPLAGAL®, 2006; TRULICITY™, 2014; VPRIV®, 2010a,b; XIGRIS®, 2008).